Application Note

Robust Low-Volume Production For Screening High-Value Nanoparticle Materials

GettyImages-1287846309-research-lab-computer-graph-data

In 2018, the FDA approval of Patisiran, a lipid nanoparticle (LNP) formulation and the first small interfering RNA therapeutic to receive FDA approval, established LNPs as the premier technology for non-viral RNA delivery. Concurrently, the NanoAssemblr® platform, which harnesses microfluidic mixing, has been demonstrated as a simple, robust and scalable production method for LNPs encapsulating various types of nucleic acids with near 100% encapsulation efficiencies. LNPs provide a versatile option for gene knockdown or gene expression studies in vitro and in vivo. The NanoAssemblr Spark™ exploits an additional advantage of microfuidic mixing: microliter-scale formulation that conserves high-value materials such as novel lipids and mRNA. This unique combination of ultra-low volume formulations with a rapid, simple and reproducible process makes Spark an ideal platform for screening and early preclinical development of mRNA-LNP formulations. Effective screening programs can significantly narrow the parameter space for developing and optimizing next-generation delivery technologies and nanoparticle therapeutics.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene